Intersect ENT is a health care equipment & supplies business based in the US. Intersect ENT shares (XENT) are listed on the NASDAQ and all prices are listed in US Dollars. Intersect ENT employs 433 staff and has a trailing 12-month revenue of around $106.7 million.
Our top picks for where to buy Intersect ENT stock
How to buy Intersect ENT stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – XENT. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Intersect ENT stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Intersect ENT stock price (NASDAQ: XENT)
Use our graph to track the performance of XENT stocks over time.Intersect ENT shares at a glance
Latest market close | $28.24 |
---|---|
52-week range | $0.00 - $0.00 |
50-day moving average | $27.83 |
200-day moving average | $27.38 |
Wall St. target price | $28.25 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-4.80 |
Is it a good time to buy Intersect ENT stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Intersect ENT price performance over time
Historical closes compared with the close of $28.24 from 2022-05-13
1 week (2024-08-27) | N/A |
---|---|
1 month (2024-08-03) | N/A |
3 months (2024-06-03) | N/A |
6 months (2024-03-03) | N/A |
1 year (2023-09-03) | N/A |
---|---|
2 years (2022-09-03) | N/A |
3 years (2021-09-07) | 2.80% |
5 years (2019-09-06) | 66.02% |
Intersect ENT financials
Revenue TTM | $106.7 million |
---|---|
Gross profit TTM | $76.7 million |
Return on assets TTM | -23.28% |
Return on equity TTM | -181.73% |
Profit margin | -149.54% |
Book value | $0.49 |
Market Capitalization | $954.9 million |
TTM: trailing 12 months
Intersect ENT share dividends
We're not expecting Intersect ENT to pay a dividend over the next 12 months.
Have Intersect ENT's shares ever split?
Intersect ENT's shares were split on a 1:4 basis on 10 July 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Intersect ENT shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Intersect ENT shares which in turn could have impacted Intersect ENT's share price.
Intersect ENT share price volatility
Over the last 12 months, Intersect ENT's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intersect ENT's is 1.5289. This would suggest that Intersect ENT's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Intersect ENT overview
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009.
Frequently asked questions
What percentage of Intersect ENT is owned by insiders or institutions?Currently 1.503% of Intersect ENT shares are held by insiders and 93.596% by institutions. How many people work for Intersect ENT?
Latest data suggests 433 work at Intersect ENT. When does the fiscal year end for Intersect ENT?
Intersect ENT's fiscal year ends in December. Where is Intersect ENT based?
Intersect ENT's address is: 1555 Adams Drive, Menlo Park, CA, United States, 94025 What is Intersect ENT's ISIN number?
Intersect ENT's international securities identification number is: US46071F1030 What is Intersect ENT's CUSIP number?
Intersect ENT's Committee on Uniform Securities Identification Procedures number is: 46071F103
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question